Helsinn’s innovative model is based on the in-licensing of an originator’s molecule, the internal financing and management of the drug’s development (CMC, pre-clinical, clinical) the internal production of Active Pharmaceutical Ingredients and drug product and the market orientation of the final drug product which is out-licensed to selected commercial partners world-wide.
The importance Helsinn gives to drug development is evidenced by the research and development conducted in 2006. This included:
| Number of Phase IV clinical trials |
6 |
| Number of Phase III clinical trials |
5 |
| Number of Phase II clinical trials |
1 |
| Number of Phase I clinical trials |
5 |
| Number of Pre-clinical trials |
7 |
| Number of sites used in clinical trials |
342 |
| Number of patients treated in clinical trials |
3.627 |
|
